(VIANEWS) – SPAREBANK 1 SMN (MING.OL), ABN AMRO BANK N.V. (ABN.AS), NAVAMEDIC (NAVA.OL) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. SPAREBANK 1 SMN (MING.OL)
20% sales growth and 12.31% return on equity
SpareBank 1 SMN, together with its subsidiaries, provides various banking, accounting, and real estate products and services to private individuals and companies in Norway and internationally. The company offers mortgage, car, boat, other vehicles, and consumer loans; refinancing; and current, savings, billing, business, group, tax deduction, currency, and deposit accounts. It also provides BSU house savings for young people; fixed interest deposits; stocks and investments; cash services; and payments. In addition, the company offers vehicle, housing and travel, person, animal, and valuables insurance services; property buying and selling advisory services; and mobile and online banking, and various cards. Further, it offers loans and financing, including bank guarantees, business and construction loans, operating credit for agriculture, factoring, guarantees, leasing, and overdrafts; various pension products; and business and personal insurance products. Additionally, the company provides document collection, letter of credit, future business, and currency option services; and services, including accounting and payroll, HR, taxes and duties, and transfer of ownership, as well as IT solutions. It offers real estate agency, advisory, and external and equity financing services. SpareBank 1 SMN was founded in 1823 and is headquartered in Trondheim, Norway.
Earnings Per Share
As for profitability, SPAREBANK 1 SMN has a trailing twelve months EPS of kr11.94.
PE Ratio
SPAREBANK 1 SMN has a trailing twelve months price to earnings ratio of 11.41. Meaning, the purchaser of the share is investing kr11.41 for every norwegian krone of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 12.31%.
Dividend Yield
As stated by Morningstar, Inc., the next dividend payment is on Mar 29, 2023, the estimated forward annual dividend rate is 6.5 and the estimated forward annual dividend yield is 4.72%.
Sales Growth
SPAREBANK 1 SMN’s sales growth is 22.7% for the ongoing quarter and 20% for the next.
Yearly Top and Bottom Value
SPAREBANK 1 SMN’s stock is valued at kr136.20 at 22:20 EST, below its 52-week high of kr139.00 and way higher than its 52-week low of kr107.60.
Volume
Today’s last reported volume for SPAREBANK 1 SMN is 68668 which is 58.18% below its average volume of 164236.
More news about SPAREBANK 1 SMN.
2. ABN AMRO BANK N.V. (ABN.AS)
19.6% sales growth and 9.3% return on equity
ABN AMRO Bank N.V. provides various banking products and services to retail, private, and business clients in the Netherlands and internationally. It operates through three segments: Personal & Business Banking, Wealth Management, and Corporate Banking. The company provides savings and deposits products; labelled residential mortgage products under the Florius brands; and consumer loans under the Alpha Credit Nederland, Credivance, Defam, Moneyou, and ABN AMRO brands. It also issues, promotes, manages, and processes credit cards; provides revolving credit card facilities and pension schemes, as well as consumer credit and mortgages; and life and non-life insurance products. In addition, it offers asset-based solutions, including working capital solutions, equipment leases and loans, and vendor lease services; private banking and wealth-management-related services; and derivatives and equity clearing services. ABN AMRO Bank N.V. was incorporated in 2009 and is headquartered in Amsterdam, the Netherlands.
Earnings Per Share
As for profitability, ABN AMRO BANK N.V. has a trailing twelve months EPS of €2.23.
PE Ratio
ABN AMRO BANK N.V. has a trailing twelve months price to earnings ratio of 6.15. Meaning, the purchaser of the share is investing €6.15 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.3%.
Sales Growth
ABN AMRO BANK N.V.’s sales growth for the next quarter is 19.6%.
Volume
Today’s last reported volume for ABN AMRO BANK N.V. is 614841 which is 82.01% below its average volume of 3419070.
Dividend Yield
According to Morningstar, Inc., the next dividend payment is on Apr 21, 2023, the estimated forward annual dividend rate is 1.6 and the estimated forward annual dividend yield is 11.54%.
More news about ABN AMRO BANK N.V..
3. NAVAMEDIC (NAVA.OL)
9.6% sales growth and 22.97% return on equity
Navamedic ASA, a pharmaceutical company, develops, produces, markets, and sells pharmaceuticals and related products in Northern Europe. The company's product portfolio includes prescription and non-prescription pharmaceuticals, as well as medical nutrition products, medical devices, food supplements, and cosmetics. It offers medical nutrition products for various therapeutic areas, including phenylketonuria, homocystinuria, maple syrup urine disease, tyrosinemia, methylmalonic acidemia/propionic acidemia, glutaric aciduria, isovaleric acidemia, and urea cycle disorders, as well as products for glycogen storage diseases and renal diseases, fat metabolism, malnutrition, and ketogenic diet. In addition, the company provides consumer health products consisting of non-prescription drugs and health care products for pain relief, cough and cold, gastro, obesity, women's health, and others primarily through pharmacies and drugstores; specialty pharmaceutical products in various therapeutic areas comprising dermatology, wound care, urology, and obesity; and branded generics, including cardiology products and antibiotics. It sells, markets, and distributes its products to hospitals, patients, and pharmacies. The company was formerly known as Glucomed AS and changed its name to Navamedic ASA in 2004. Navamedic ASA was incorporated in 2002 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, NAVAMEDIC has a trailing twelve months EPS of kr1.76.
PE Ratio
NAVAMEDIC has a trailing twelve months price to earnings ratio of 22.44. Meaning, the purchaser of the share is investing kr22.44 for every norwegian krone of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 22.97%.
Yearly Top and Bottom Value
NAVAMEDIC’s stock is valued at kr39.50 at 22:20 EST, below its 52-week high of kr43.60 and way above its 52-week low of kr25.00.
Sales Growth
NAVAMEDIC’s sales growth is 93.3% for the ongoing quarter and 9.6% for the next.
More news about NAVAMEDIC.
